title: Human umbilical cord blood-derived CD34-positive endothelial progenitor cells stimulate osteoblastic differentiation of cultured human periosteal-derived osteoblasts.
abstract: The aim of this study was to examine the effects of human umbilical cord blood-derived CD34-positive endothelial progenitor cells (CD34+ EPCs) on osteoblastic differentiation of cultured human periosteal-derived osteoblasts (POs). CD34+ cells from human umbilical cord blood were sorted to purify more EPCs in characterization. These sorted cells showed CD31, VE-cadherin, and KDR expression as well as CD34 expression and formed typical tubes in Matrigel. These sorted cells were referred to as human cord blood-derived CD34+ EPCs. In in vivo bone formation using a miniature pig model, the newly formed bone was clearly examined in defects filled with polydioxanone/pluronic F127 (PDO/Pluronic F127) scaffolds containing either human umbilical cord blood-derived CD34+ EPCs and POs or human umbilical vein endothelial cells (HUVEC) and POs; however, the new bone had the greatest density in the defect treated with CD34+ EPCs and POs. Osteoblastic phenotypes of cultured human POs using ALP activity and von Kossa staining were also more clearly found in CD34+ EPC-conditioned medium than CD34-negative (CD34-) cell-conditioned medium, whereas HUVEC-conditioned medium had an intermediate effect. PCR array for common cytokines and growth factors showed that the secretion of interleukin (IL)-1β was significantly higher in CD34+ EPCs than in HUVEC, followed by level in CD34- cells. In addition, IL-1β also potently and dose dependently increased ALP activity and mineralization of POs in culture. These results suggest that human umbilical cord blood-derived CD34+ EPCs stimulates osteoblastic differentiation of cultured human POs. The functional role of human umbilical cord blood-derived CD34+ EPCs in increasing the osteogenic phenotypes of cultured human POs may depend on IL-1β secreted from human umbilical cord blood-derived CD34+ EPCs.
authors.affiliation: 1 Department of Advanced Materials, College of Life Science and Nano Technology, Hannam University , Daejeon, South Korea .
authors.forename: Jin-Ho
authors.initials: JH
authors.lastname: Lee
authors.forename: Young-Sool
authors.initials: YS
authors.lastname: Hah
authors.forename: Hee-Young
authors.initials: HY
authors.lastname: Cho
authors.forename: Jin-Hyun
authors.initials: JH
authors.lastname: Kim
authors.forename: Se-Heang
authors.initials: SH
authors.lastname: Oh
authors.forename: Bong-Wook
authors.initials: BW
authors.lastname: Park
authors.forename: Young-Hoon
authors.initials: YH
authors.lastname: Kang
authors.forename: Mun-Jeoung
authors.initials: MJ
authors.lastname: Choi
authors.forename: Jeong-Kyu
authors.initials: JK
authors.lastname: Shin
authors.forename: Gyu-Jin
authors.initials: GJ
authors.lastname: Rho
authors.forename: Ryoung-Hoon
authors.initials: RH
authors.lastname: Jeon
authors.forename: Hee-Chun
authors.initials: HC
authors.lastname: Lee
authors.forename: Gyoo-Cheon
authors.initials: GC
authors.lastname: Kim
authors.forename: Uk-Kyu
authors.initials: UK
authors.lastname: Kim
authors.forename: Jong-Ryoul
authors.initials: JR
authors.lastname: Kim
authors.forename: Chang-Il
authors.initials: CI
authors.lastname: Lee
authors.forename: June-Ho
authors.initials: JH
authors.lastname: Byun
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D018952:Antigens, CD34 / Q000378:metabolism*; D017252:CD3 Complex / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D017077:Culture Media, Conditioned / Q000494:pharmacology; D004338:Drug Combinations; D042783:Endothelial Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D061307:Human Umbilical Vein Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D053583:Interleukin-1beta / Q000494:pharmacology; D007797:Laminin / Q000494:pharmacology; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D010012:Osteogenesis / Q000187:drug effects; D010521:Periosteum / Q000166:cytology*; D020442:Poloxamer / Q000494:pharmacology; D016687:Polydioxanone / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D011509:Proteoglycans / Q000494:pharmacology; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D054457:Tissue Scaffolds / Q000737:chemistry
chemical_list: D018952:Antigens, CD34; D017252:CD3 Complex; D017077:Culture Media, Conditioned; D004338:Drug Combinations; D053583:Interleukin-1beta; D007797:Laminin; D011509:Proteoglycans; D020442:Poloxamer; C059485:matrigel; D016687:Polydioxanone; D003094:Collagen; D000469:Alkaline Phosphatase